Obesity is increasingly recognized as a chronic, relapsing disease with metabolic, mechanical, and inflammatory consequences extending far beyond excess body weight alone. In rheumatology, obesity has important implications for inflammatory arthritis, particularly rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Through adipose tissue–driven inflammation, altered biomechanics, and immune dysregulation, obesity contributes to disease susceptibility, complicates clinical assessment, and is associated with higher disease activity, poorer functional outcomes, and lower likelihood of remission in both RA and PsA. Although overall disease-modifying antirheumatic drug (DMARD) treatment strategies remain broadly similar, obesity may influence therapeutic response—most consistently with tumor necrosis factor inhibitors—and warrants attention to safety considerations such as hepatic dysfunction, metabolic comorbidity, cardiovascular risk, and weight gain. Beyond lifestyle measures, newer anti-obesity therapies including glucagon-like peptide-1 receptor agonists and dual incretin agonists such as tirzepatide offer promising opportunities to improve metabolic health and potentially enhance disease control in inflammatory arthritis.

Obesity has emerged as one of the most important and increasingly encountered comorbidities in rheumatology. It is now defined as a chronic, relapsing disease of excess adipose tissue that adversely affects metabolic, mechanical, and inflammatory pathways, far beyond a cosmetic concern or lifestyle challenge. Its rising prevalence across age groups has made obesity a global epidemic with major implications for rheumatic and musculoskeletal diseases (RMDs), particularly rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. Although body mass index (BMI) remains an imperfect surrogate for adiposity, it continues to be the most widely used clinical measure. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) classify BMI 25–29.9 kg/m² as overweight and ≥30 kg/m² as obesity. However, ethnicity-specific thresholds are increasingly relevant. In Asian and Indian populations, metabolic risk occurs at lower BMI levels; therefore, BMI >23 kg/m² is considered overweight and >25 kg/m² obesity.

Clinical assessment, however, must extend beyond BMI. Waist circumference and central adiposity are key markers of cardiometabolic risk and should be routinely assessed. Evaluation of obesity-related metabolic and end-organ consequences—including insulin resistance, prediabetes or diabetes, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), sleep apnea, cardiovascular dysfunction, and mechanical limitation—is equally important. The Edmonton Obesity Staging System (EOSS) provides a clinically useful framework that incorporates obesity-related complications and functional impact rather than relying solely on anthropometry.

Obesity has well-established associations with several musculoskeletal disorders, including osteoarthritis, low back pain, osteopenia and osteoporosis, plantar fasciitis, carpal tunnel syndrome, fibromyalgia, and gout. Increasingly, attention has shifted toward its influence on inflammatory arthritis, where obesity affects disease susceptibility, assessment, treatment response, and long-term outcomes.

Obesity and Rheumatoid Arthritis: More Than a Comorbidity

The relationship between obesity and RA is increasingly recognized as bidirectional. Obesity may predispose individuals to inflammatory disease through chronic low-grade inflammation, while RA itself may contribute to metabolic dysfunction and metabolic syndrome. Studies consistently report a higher prevalence of metabolic syndrome among patients with RA, even early in disease, highlighting the close interplay between inflammation and metabolism.

Adipose tissue is now viewed as an active endocrine and immune organ rather than passive fat storage. Excess adiposity promotes secretion of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), leptin, and adipokines, creating a persistent pro-inflammatory milieu that may amplify synovial inflammation, pain sensitization, and therapeutic resistance. Altered gut microbiota and obesity-related biomechanical stress further contribute to disease expression.

Clinical assessment of inflammatory arthritis can be particularly challenging in obesity. Increased soft tissue and altered joint contours may obscure swelling and tenderness, creating discordance between clinical examination and imaging findings. Ultrasound-based studies have demonstrated higher swollen joint counts compared with clinical assessment among overweight and obese RA patients, emphasizing that inflammatory burden may be underestimated or clinically difficult to interpret.

Obesity influences disease activity and treatment outcomes in RA. Evidence consistently demonstrates that obese patients are less likely to achieve remission and more likely to report greater pain, fatigue, and functional limitation. Failure to achieve Disease Activity Score-28 (DAS28) remission is particularly common, with stronger associations observed among women and smokers. Importantly, this excess disease burden often reflects heightened inflammatory signaling and patient-reported symptoms rather than proportionately greater swollen joint counts.

The clinical consequence is increasingly relevant: obesity contributes to difficult-to-treat RA. Alongside fibromyalgia and osteoarthritis, obesity represents an independent risk factor for persistent symptoms, suboptimal treatment response, and difficulty in achieving therapeutic targets.

Obesity and Psoriatic Arthritis: A Shared Inflammatory Axis

If obesity complicates RA, its relationship with PsA appears even more intertwined.

Up to half of individuals with psoriatic disease have obesity, and current evidence suggests a probable causal association. Increased adiposity is linked not only to psoriasis severity but also to a greater risk of PsA development and progression.

The mechanistic overlap is biologically compelling. Dysfunctional adipose tissue promotes systemic inflammation through adipokines and cytokine release, while obesity-associated gut dysbiosis and immune dysregulation further sustain inflammatory pathways. Mechanical stress at entheses—particularly in weight-bearing regions—may act as an additional trigger for inflammation in genetically predisposed individuals. Collectively, these pathways create a self-perpetuating inflammatory loop in which obesity and PsA reinforce one another.

Clinically, obesity in PsA is associated with higher disease activity, poorer physical function, and a lower likelihood of achieving minimal disease activity. Similar to RA, obesity complicates disease assessment and magnifies pain and disability. Increasing evidence also links obesity with treatment-refractory or difficult-to-manage PsA, particularly among patients early in the disease course or those with prominent synovio-entheseal involvement.

Therapeutic Implications: Does Weight Influence DMARD Response?

Obesity has important therapeutic implications in inflammatory arthritis. Excess adiposity may influence treatment response through persistent systemic inflammation, altered drug pharmacokinetics, increased volume of distribution, and enhanced drug clearance. Consequently, therapeutic effectiveness may vary according to both drug class and body composition.

Among conventional synthetic disease-modifying antirheumatic drugs (DMARDs), methotrexate may demonstrate somewhat reduced effectiveness in obese individuals and carries greater concern for hepatic toxicity, particularly in the presence of MASLD or metabolic dysfunction. Leflunomide similarly warrants caution when clinically significant liver disease coexists.

The most consistent evidence of reduced efficacy relates to TNF-inhibitors. Across RA and PsA, obesity has been associated with lower remission rates, diminished drug persistence, and poorer clinical outcomes. Increased cytokine burden and altered drug handling are believed to contribute to this observation.

In contrast, several non-TNF biologics appear less influenced by obesity. Abatacept and rituximab generally maintain efficacy irrespective of body weight, while findings with tocilizumab remain variable. Although obesity is characterized by activation of interleukin-17 (IL-17) and interleukin-23 (IL-23) pathways, current evidence does not suggest a comparable decline in efficacy of IL-17 or IL-23 inhibitors. Likewise, Janus kinase (JAK) inhibitors appear relatively less affected by obesity-related pharmacokinetic alterations.

Taken together, obesity appears to exert its greatest negative impact on TNF-inhibitor response, whereas several non-TNF biologics and targeted synthetic agents may preserve therapeutic effectiveness.

Safety Considerations and Weight Reduction Strategies

Obesity also influences treatment safety and monitoring. MASLD and hepatic dysfunction may limit methotrexate or leflunomide use and warrant closer laboratory surveillance. Glucocorticoid-associated weight gain and metabolic deterioration remain major concerns in obese individuals. Obesity-associated venous thromboembolism and cardiovascular burden require careful consideration when evaluating therapies with thrombosis-related concerns, including JAK inhibitors. Similarly, elevated cardiovascular risk influences non-steroidal anti-inflammatory drug (NSAID) prescribing. Thus, obesity should not merely be documented as a comorbidity—it should actively inform therapeutic selection, monitoring intensity, and long-term risk assessment.

Obesity management, both generally and within RMDs, rests on three pillars: lifestyle intervention, pharmacotherapy, and bariatric surgery. Lifestyle modification remains foundational but often produces modest long-term weight reduction. Nevertheless, even moderate weight loss may improve mobility, metabolic health, pain, and therapeutic responsiveness.

The anti-obesity therapeutic landscape has evolved rapidly. Glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, along with dual incretin agonists such as tirzepatide, provide substantial and sustained weight loss through appetite suppression and metabolic regulation. Their established benefits in osteoarthritis, particularly through reduced mechanical loading and pain improvement, are increasingly recognized. Whether these agents may favorably influence inflammatory burden and treatment response in RA and PsA remains an active and promising area of investigation.

For severe obesity, bariatric surgery remains the most effective strategy for durable weight reduction. Beyond metabolic benefits, surgery may improve inflammatory and functional outcomes, although careful long-term surveillance for nutritional deficiency and skeletal complications remains essential.

The traditional view of obesity as a passive comorbidity in inflammatory arthritis is rapidly fading. In both RA and PsA, obesity influences disease susceptibility, clinical assessment, disease activity, therapeutic response, and long-term outcomes. As obesity therapeutics advance and our understanding of adipose–immune interactions deepens, weight management may increasingly become an integral pillar of precision rheumatology. When weight weighs on joints, the burden extends beyond mechanics—amplifying inflammation, modulating disease activity, and influencing therapeutic success.

Suggested Readings

1. Haberman RH, Ogdie A, Merola JF, Scher JU, Eder L. The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies. Nat Rev Rheumatol. 2026 Mar;22(3):151–64.
2. Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev. 2023 Jul;22(7):103357.
3. Luciano N, Barone E, Brunetta E, D’Isanto A, De Santis M, Ceribelli A, et al. Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender. Arthritis Res Ther. 2025 Jan 3;27(1):2.
4. Tidblad L, Öberg Sysojev A, Delcoigne B, Klareskog L, Alfredsson L, Askling J, et al. In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity. RMD Open. 2025 Apr 15;11(2). Available from: http://dx.doi.org/10.1136/rmdopen-2025-005430
5. Sattar N, Sattar LJ, McInnes IB, Siebert S, Ferguson LD. Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act. Ann Rheum Dis. 2025 Jun;84(6):894–8.